Progress on CAR-T Cell Therapy for Hematological Malignancies

Overview

Journal Zhejiang Da Xue Xue Bao Yi Xue Ban

Specialty General Medicine

Date 2022 Sep 26

PMID 36161291

Authors

Kejia Hu

Yue Huang

Yongxian Hu

He Huang

Affiliations

Soon will be listed here.

Abstract

Chimeric antigen receptor (CAR) T cell therapy is an effective treatment for hematological malignancies, which have experienced the development of CD19 CAR-T cells for B lymphoblastic leukemia and lymphoma, B cell maturation antigen (BCMA) CAR-T cells for multiple myeloid, and more recently, the development of CD7 CAR-T cells for T cell malignancies. There are more obstacles for myeloid malignancies compared to other hematological malignancies in this field, thus concerning researches are in more diverse ways. In order to obtain more effective clinical CAR-T cells with lower side effects, scientists have developed multi-target CAR-T cells, universal CAR-T cells, as well as CAR-T cells, CAR-NK cells, CAR-iMac cells derived from induced pluripotent stem cells (iPSC) by genetic engineering. Chinese scientists have made significant contribution to the invention and manufacture of origin CAR-T cells and the establishment of an intact clinical research system. This review introduces the latest progress involving CAR-T cell therapy for hematological malignancies including B lymphoblastic malignancies, T lymphoblastic malignancies and myeloid malignancies, and also discuss the future developments including multi-target, universal and iPSC-derived CAR-related cell therapy.

Citing Articles

Umbilical cord blood and cord tissue banking as somatic stem cell resources to support medical cell modalities.

Nagamura-Inoue T, Nagamura F Inflamm Regen. 2023; 43(1):59.

PMID: 38053217 PMC: 10696687. DOI: 10.1186/s41232-023-00311-4.

References

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Maude S, Frey N, Shaw P, Aplenc R, Barrett D, Bunin N . Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507-17. PMC: 4267531. DOI: 10.1056/NEJMoa1407222. View

Zhang M, Zhou L, Zhao H, Zhang Y, Wei G, Hong R . Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. Clin Cancer Res. 2021; 27(23):6384-6392. PMC: 9401500. DOI: 10.1158/1078-0432.CCR-21-2031. View

Cui Q, Qian C, Xu N, Kang L, Dai H, Cui W . CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol. 2021; 14(1):82. PMC: 8152118. DOI: 10.1186/s13045-021-01092-4. View

Mei H, Li C, Jiang H, Zhao X, Huang Z, Jin D . A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma. J Hematol Oncol. 2021; 14(1):161. PMC: 8501733. DOI: 10.1186/s13045-021-01170-7. View

Zhang L, Tian L, Dai X, Yu H, Wang J, Lei A . Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions. J Hematol Oncol. 2020; 13(1):153. PMC: 7656711. DOI: 10.1186/s13045-020-00983-2. View

Xie L, Ma L, Liu S, Chang L, Wen F . Chimeric antigen receptor T cells targeting CD7 in a child with high-risk T-cell acute lymphoblastic leukemia. Int Immunopharmacol. 2021; 96:107731. DOI: 10.1016/j.intimp.2021.107731. View

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D . Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380(18):1726-1737. PMC: 8202968. DOI: 10.1056/NEJMoa1817226. View

Myers R, Li Y, Leahy A, Barrett D, Teachey D, Callahan C . Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2021; 39(27):3044-3055. PMC: 9851702. DOI: 10.1200/JCO.20.03458. View

10.

Tashiro H, Sauer T, Shum T, Parikh K, Mamonkin M, Omer B . Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. Mol Ther. 2017; 25(9):2202-2213. PMC: 5589064. DOI: 10.1016/j.ymthe.2017.05.024. View

11.

Ratajczak M, Bujko K, Wojakowski W . Stem cells and clinical practice: new advances and challenges at the time of emerging problems with induced pluripotent stem cell therapies. Pol Arch Med Wewn. 2016; 126(11):879-890. DOI: 10.20452/pamw.3644. View

12.

Shimabukuro-Vornhagen A, Boll B, Schellongowski P, Valade S, Metaxa V, Azoulay E . Critical care management of chimeric antigen receptor T-cell therapy recipients. CA Cancer J Clin. 2021; 72(1):78-93. DOI: 10.3322/caac.21702. View

13.

Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B . CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunol Res. 2021; 9(9):1061-1070. DOI: 10.1158/2326-6066.CIR-20-0675. View

14.

Couchie D, Fages C, Bridoux A, Rolland B, Tardy M, Nunez J . Microtubule-associated proteins and in vitro astrocyte differentiation. J Cell Biol. 1985; 101(6):2095-103. PMC: 2114029. DOI: 10.1083/jcb.101.6.2095. View

15.

Yu S, Yi M, Qin S, Wu K . Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019; 18(1):125. PMC: 6701025. DOI: 10.1186/s12943-019-1057-4. View

16.

Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W . Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021; 39(30):3340-3351. DOI: 10.1200/JCO.21.00389. View

17.

Shah N, Johnson B, Schneider D, Zhu F, Szabo A, Keever-Taylor C . Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020; 26(10):1569-1575. DOI: 10.1038/s41591-020-1081-3. View

18.

Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M . Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. 2022; 602(7897):503-509. PMC: 9166916. DOI: 10.1038/s41586-021-04390-6. View

19.

Tettamanti S, Marin V, Pizzitola I, Magnani C, Giordano Attianese G, Cribioli E . Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013; 161(3):389-401. DOI: 10.1111/bjh.12282. View

20.

Abramson J, Palomba M, Gordon L, Lunning M, Wang M, Arnason J . Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020; 396(10254):839-852. DOI: 10.1016/S0140-6736(20)31366-0. View